Prof. Binfeng Lu

Department of Immunology

University of Pittsburgh School of Medicine, USA

Email: binfeng@pitt.edu

Qualifications

2009   Associate Professor, Immunology, University of Pittsburgh, USA
2003   Postdoctoral Training, Section of Immunobiology, Yale University, USA
1998   Ph.D., Degree, Columbia University New York, USA

Publications (selected)

1. Ye, Fan & Huang, Jianing & Cheng, Xiaoli & Chen, Shih & Huang, Fang & Huang, Wen-Chin & Hua, Botong & Li, Ella & Jiang, Jenny & Lin, Hanna & Siegel, Matthew & Liao, Eric & Wang, Ji & Yue, Bella & Shi, Wenli & Xu, Yanghua & Wang, Xin & Wang, Jiaming & Yan, Yuyuan & Zhong, Ziyang. (2025). AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity. Frontiers in Immunology. 16. 10.3389/fimmu.2025.1537466.

2. Zhang, Han & Lu, Binfeng & Lu, Xinghua & Saeed, Anwaar & Chen, Lujia. (2024). Current transcriptome database and biomarker discovery for immunotherapy by immune checkpoint blockade. bioRxiv : the preprint server for biology. 10.1101/2024.12.09.627506.

3. Chen, Lujia & Zhang, Han & Lu, Binfeng & Cooper, Gregory & Saeed, Anwaar & Lu, Xinghua. (2024). Effect of deconvoluting single-cell transcriptomics on cellular programs regulated by cell-cell communication in colorectal cancer.. Journal of Clinical Oncology. 42. 59-59. 10.1200/JCO.2024.42.23_suppl.59.

4. Wu, Shaoxian & Jiang, Hongwei & Fang, Zhang & Wu, You & Jiao, Jing & Fang, Weiwei & Wu, Yue & Lang, Yanyan & Chen, Ning & Zhong, Ziyang & Chen, Lujun & Zheng, Xiao & Lu, Binfeng & Jiang, Jingting. (2024). Enhanced abscopal anti-tumor response via a triple combination of thermal ablation, IL-21, and PD-1 inhibition therapy. Cancer Immunology, Immunotherapy. 73. 138. 10.1007/s00262-024-03718-1.

5. Zhang, Han & Lu, Xinghua & Lu, Binfeng & Gullo, Giuseppe & Chen, Lujia. (2024). Measuring the composition of the tumor microenvironment with transcriptome analysis: past, present and future. Future oncology (London, England). 20. 10.2217/fon-2023-0658.                                                      

6. Luo, Zhangyi & Huang, Yixian & Batra, Neelu & Chen, Yuang & Huang, Haozhe & Wang, Yifei & Zhang, Ziqian & Li, Shichen & Chen, Chien-Yu & Wang, Zehua & Sun, Jingjing & Wang, Qiming & Yang, Da & Lu, Binfeng & Conway, James & Li, Lu-Yuan & Yu, Ai-Ming & Li, Song. (2024). Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy. Nature Communications. 15. 10.1038/s41467-023-44572-6.

7. Zhang, Han & Lu, Xinghua & Lu, Binfeng & Chen, Lujia. (2023). Measuring the composition of tumor microenvironment from transcriptome analysis: past, now and future. 10.13140/RG.2.2.28624.28167.                      

8. Zhang, Han & Lu, Xinghua & Lu, Binfeng & Chen, Lujia. (2023). scGEM: Unveiling the Nested Tree-Structured Gene Co-Expressing Modules in Single Cell Transcriptome Data. Cancers. 15. 4277. 10.3390/cancers15174277.

9. Sun, Runzi & Zhao, Hongyu & Gao, David & Ni, Andrew & Li, Haochen & Chen, Lujia & Lu, Xinghua & Chen, Kong & Lu, Binfeng. (2023). Amphiregulin couples IL1RL1+ regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity. Science advances. 9. eadd7399. 10.1126/sciadv.add7399.

10. Wu, Shaoxian & Huang, Hao & Sun, Runzi & Gao, David & Ye, Fan & Huang, Jianing & Li, Ella & Ni, Andrew & Lu, Kevin & Chen, Kong & Jiang, Jingting & Morel, Penelope & Zhong, Ziyang & Lu, Binfeng. (2023). Synergism between IL21 and anti-PD-1 combination therapy is underpinned by coordinated reprogramming of the immune cellular network in the tumor microenvironment. Cancer Research Communications. 3. 10.1158/2767-9764.CRC-23-0012.

11. Chen, Yuang & Huang, Yixian & Li, Qinzhe & Luo, Zhangyi & Zhang, Ziqian & Huang, Haozhe & Sun, Jingjing & Zhang, LinXinTian & Sun, Runzi & Bain, Daniel & Conway, James & Lu, Binfeng & Li, Song. (2022). Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy. Nature Nanotechnology. 18. 1-12. 10.1038/s41565-022-01266-2.

12. Wang, Weihong & Wu, Shaoxian & Cen, Zhanpeng & Zhang, Yixin & Chen, Yuang & Huang, Yixian & Cillo, Anthony & Prokopec, Joshua & Quarato, Giovanni & Vignali, Dario & Stewart-Ornstein, Jacob & Li, Song & Lu, Binfeng & Gong, Yi-Nan. (2022). Mobilizing phospholipids on tumor plasma membrane implicates phosphatidylserine externalization blockade for cancer immunotherapy. Cell Reports. 41. 111582. 10.1016/j.celrep.2022.111582.

13. Zhu, Zhi & Mcgray, Aj & Jiang, Weijian & Lu, Binfeng & Kalinski, Pawel & Guo, Zong Sheng. (2022). Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Molecular Cancer. 21. 10.1186/s12943-022-01664-z.

14. Li, Yang & Gao, David & Yi, Lixian & Gao, Fei & Sun, Runzi & Lu, Kevin & Xu, Junchi & Shoush, Jason & Kykrou, Zoi & Liang, Minxin & Lu, Binfeng. (2022). Tumor suppressor p53 deficiency increases tumor immunogenicity through promoting IL33-mediated anti-tumor immune responses. 10.1101/2022.09.11.507505.

15. Chen, Lujun & Huang, Hao & Zheng, Xiao & Li, Yuan & Chen, Junjun & Tan, Bo & Liu, Yingting & Sun, Runzi & Xu, Bin & Yang, Min & Li, Bin & Wu, Changping & Lu, Binfeng & Jiang, Jingting. (2022). IL1R2 increases regulatory T cell population in the tumor microenvironment by enhancing MHC-II expression on cancer-associated fibroblasts. Journal for ImmunoTherapy of Cancer. 10. e004585. 10.1136/jitc-2022-004585.

16. Gao, David & Li, Yang & Shoush, Jason & Sun, Runzi & Lu, Binfeng. (2022). Abstract 1326: Loss of p53 sensitizes tumor cells to immune checkpoint blockade therapy via upregulation of IL-33. Cancer Research. 82. 1326-1326. 10.1158/1538-7445.AM2022-1326.

17. Sun, Runzi & Gao, David & Shoush, Jason & Lu, Binfeng. (2022). The IL-1 family in tumorigenesis and antitumor immunity. Seminars in Cancer Biology. 86. 10.1016/j.semcancer.2022.05.002.

18. Tang, Peijun & Chen, Xingnian & Xu, Junchi & Hu, Yunlong & Ye, Zhijian & Wang, Xiafang & Xiao, Yumei & Shen, Xinghua & Zhang, Jianping & Feng, Yanjun & Shi, Cuilin & Yu, Xin & Yi, Lixian & Chen, Xinchun & Lu, Binfeng & Xu, Ping & Sun, Zhongwen & Wu, Meiying. (2022). Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis. Journal of Immunology Research. 2022. 10.1155/2022/2943113.                                                          

19. Xie, Yang & Sun, Runzi & Gao, Li & Guan, Jibin & Wang, Jingyuan & Bell, Aaron & Zhu, Junjie & Zhang, Min & Xu, Meishu & Lu, Peipei & Cai, Xinran & Ren, Songrong & Pengfei, Xu & Monga, Satdarshan (Paul) & Ma, Xiaochao & Yang, Da & Liu, Yulan & Lu, Binfeng & Xie, Wen. (2022). Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma. Hepatology Communications. 6. 10.1002/hep4.1880.

20. Wan, Zhuoya & Sun, Runzi & Liu, Yang-Wuyue & Li, Sihan & Sun, Jingjing & Li, Jiang & Zhu, Junjie & Moharil, Pearl & Zhang, Bei & Ren, Pengfei & Ren, Guolian & Zhang, Min & Ma, Xiaochao & Dai, Shuangshuang & Yang, Da & Lu, Binfeng & Li, Song. (2021). Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. Science Advances. 7. 10.1126/sciadv.abj4226.

Profile Details

https://scholar.google.com/citations?user=jy9qpOkAAAAJ&hl=zh-CN